Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Synairgen plc

COVID-19 R&D: Pharma’s Path Ahead

Global research and development for preventative vaccines and therapeutics to treat COVID-19 have progressed at a rapid pace. Still, key issues remain and to the dampen the effects of virus in 2022, even greater collaboration is needed.

Outlook 2022 Coronavirus COVID-19

Coronavirus Notebook: Valneva Vaccine To Begin EU Rolling Review, Synairgen Reports Progress With Inhaled IFN-Beta

The European Parliament is pushing for more of a say in how Europe’s new emergency response authority, HERA, deals with R&D and procurement of vaccines and therapies in times of health crises. NRx Therapeutics says it will continue to seek US approval of aviptadil for COVID-19. 

Coronavirus COVID-19 Europe

NIH Study Keeps Synairgen’s Dream Of An Inhaled COVID-19 Therapy Alive

SNG001 has moved into a Phase III open label trial in which it must prove its non-inferiority against Regeneron's monoclonal antibody cocktail.

Companies Commercial

Stock Watch: Post-Pandemic Life Science Market Dynamics

Factors in addition to the rejuvenation of pharmaceutical revenues and biotechnology product failures are likely to pull in opposite directions at the sector’s recovery from the pandemic.

Stock Watch Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
    • Drug Discovery Tools
      • ADMET
  • Other Names / Subsidiaries
    • Synairgen Research Ltd
UsernamePublicRestriction

Register